Jefferies Adjusts CVS Health (NYSE:CVS) Price Target to $110 From $143
Jefferies Adjusts CVS Health (NYSE:CVS) Price Target to $110 From $143, Maintains Buy Rating。
Jefferies Adjusts CVS Health (NYSE:CVS) Price Target to $110 From $143 Read Post »
Health Care
Needham maintains Biogen (NASDAQ:BIIB) $320 price target
Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $320 price target.
Needham maintains Biogen (NASDAQ:BIIB) $320 price target Read Post »
Stifel lowers Biogen (NASDAQ:BIIB) price target from $324 to $320
Stifel analyst Paul Matteis maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $324 to $320.
Stifel lowers Biogen (NASDAQ:BIIB) price target from $324 to $320 Read Post »
Biogen (NASDAQ:BIIB) Q2 Non-GAAP Earnings, Revenue Fall; Full-Year 2023 Outlook Maintained
Biogen (NASDAQ:BIIB) reported Q2 non-GAAP earnings of $4.02 per diluted share, down from $5.25 a year earlier. Analysts polled by Capital IQ expected $3.76. Total revenue for the quarter ended June 30 was $2.46 billion, down from $2.59 billion a year earlier. Analysts surveyed by Capital IQ expected $2.36 billion. Biogen said it continues to expect full-year 2023 adjusted EPS of $15 to $16. Analysts polled by Capital IQ are expecting adjusted EPS of $15.43. Revenue for the year is expected to decline by mid-single-digit percentage from a year earlier.
Raymond James announces Danaher (NYSE:DHR) Price Target of $270
Raymond James analyst Andrew Cooper initiates coverage on Danaher (NYSE:DHR) with a Outperform rating and announces Price Target of $270.
Raymond James announces Danaher (NYSE:DHR) Price Target of $270 Read Post »
Danaher (NYSE:DHR) Q2 Adjusted EPS $2.05 Beats $2.01 Estimate
Danaher (NYSE:DHR) Q2 Adjusted EPS $2.05 Beats $2.01 Estimate, Sales $7.16B Beat $7.11B Estimate.
Danaher (NYSE:DHR) Q2 Adjusted EPS $2.05 Beats $2.01 Estimate Read Post »
Morgan Stanley Adjusts Price Target on Intuitive Surgical (NASDAQ:ISRG) to $330 From $310
Morgan Stanley Adjusts Price Target on Intuitive Surgical (NASDAQ:ISRG) to $330 From $310, Maintains Equalweight Rating.
Barclays lowers Gilead Sciences (NASDAQ:GILD) price target from $81 to $80
Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $81 to $80.
Barclays lowers Gilead Sciences (NASDAQ:GILD) price target from $81 to $80 Read Post »
UBS Adjusts Amgen (NASDAQ:AMGN) Price Target to $250 From $248
UBS Adjusts Amgen (NASDAQ:AMGN) Price Target to $250 From $248, Maintains Neutral Rating.
UBS Adjusts Amgen (NASDAQ:AMGN) Price Target to $250 From $248 Read Post »
Wells Fargo raises Intuitive Surgical (NASDAQ:ISRG) price target from $310 to $386
Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:ISRG) with a Overweight and raises the price target from $310 to $386.
Wells Fargo raises Intuitive Surgical (NASDAQ:ISRG) price target from $310 to $386 Read Post »
RBC Capital Boosts Price Target on Intuitive Surgical (NASDAQ:ISRG) to $360 From $355
RBC Capital Boosts Price Target on Intuitive Surgical (NASDAQ:ISRG) to $360 From $355, Cites Q2 Beat, Volume Growth, Keeps Outperform Rating。
RBC Capital Boosts Price Target on Intuitive Surgical (NASDAQ:ISRG) to $360 From $355 Read Post »
Raymond James raises Intuitive Surgical (NASDAQ:ISRG) price target from $323 to $368
Raymond James analyst Jason Bednar maintains Intuitive Surgical (NASDAQ:ISRG) with a Outperform and raises the price target from $323 to $368.
Raymond James raises Intuitive Surgical (NASDAQ:ISRG) price target from $323 to $368 Read Post »